Technical Analysis for LUCD - Lucid Diagnostics Inc.

Grade Last Price % Change Price Change
D 7.14 2.00% 0.14
LUCD closed up 2.0 percent on Tuesday, December 7, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical LUCD trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.00%
Hammer Candlestick Bullish 2.00%
Lower Bollinger Band Walk Weakness 2.00%
New 52 Week Low Weakness 2.00%
Older End-of-Day Signals for LUCD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
Up 3% about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Up 2% about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Gastroenterology Digestive Diseases Esophageal Cancer Gastroesophageal Reflux Disease

Is LUCD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.52
52 Week Low 6.25
Average Volume 244,586
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 8.66
10-Day Moving Average 7.65
Average True Range 0.93
ADX 36.63
+DI 8.53
-DI 31.06
Chandelier Exit (Long, 3 ATRs) 8.06
Chandelier Exit (Short, 3 ATRs) 9.03
Upper Bollinger Bands 11.00
Lower Bollinger Band 6.32
Percent B (%b) 0.18
BandWidth 54.00
MACD Line -0.74
MACD Signal Line -0.57
MACD Histogram -0.1637
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.87
Resistance 3 (R3) 7.84 7.56 7.75
Resistance 2 (R2) 7.56 7.38 7.58 7.70
Resistance 1 (R1) 7.35 7.26 7.46 7.38 7.66
Pivot Point 7.08 7.08 7.13 7.09 7.08
Support 1 (S1) 6.87 6.89 6.97 6.90 6.62
Support 2 (S2) 6.59 6.78 6.61 6.58
Support 3 (S3) 6.38 6.59 6.54
Support 4 (S4) 6.41